Liraglutide

Plain-English version: liraglutide is a made-in-the-lab copy of a natural hormone called GLP-1 (glucagon-like peptide-1) that your gut releases after you eat. GLP-1 tells your pancreas to release insulin, tells your stomach to empty more slowly, and tells your brain that you are full. Liraglutide switches those same signals on for much longer than the natural hormone can, which is why it lowers both appetite and blood sugar.

Structurally, liraglutide is 97% identical to human GLP-1. Its one clever modification is a fatty-acid chain (C-16 palmitic acid) attached to the peptide, which lets it stick reversibly to albumin — a carrier protein in your blood. That "hitchhiking" shields it from the enzyme (DPP-4) that destroys natural GLP-1 within minutes, stretching its half-life to about 13 hours.^[6] That is long enough for a once-daily shot, but much shorter than semaglutide's roughly 7-day half-life, which is achieved with a longer fatty-acid chain and extra tweaks. This is the single most important practical difference between the two drugs: liraglutide is daily, semaglutide is weekly.

Developed by Novo Nordisk, liraglutide reached the market as Victoza (1.2-1.8 mg) for type 2 diabetes in January 2010, after the LEAD trial program showed it meaningfully lowered HbA1c (a three-month average blood-sugar marker). In December 2014 the same molecule was approved at a higher target dose (3.0 mg) as Saxenda for chronic weight management — the first GLP-1 drug ever approved specifically as an anti-obesity medicine. Pediatric approvals followed: Victoza for children 10+ with type 2 diabetes in 2019, and Saxenda for adolescents 12-17 with obesity in December 2020.^[7]

Credibility note, stated up front: unlike most compounds covered on this site, liraglutide is not an unapproved research peptide. Its efficacy claims rest on large, placebo-controlled human randomized trials, not animal data. The only animal-derived concern is a thyroid-tumor signal in rodents, discussed in the safety section below. For the broader regulatory picture, see Are Peptides Legal?

Takeaway first: liraglutide works by pretending to be your natural gut hormone GLP-1, but sticking around far longer. It nudges several organs at once — pancreas, brain, stomach, and heart — which is why it lowers both weight and blood sugar and, in high-risk patients, protects the heart.

The GLP-1 receptor it targets is found throughout the body, and liraglutide activates it in several places:

• Pancreatic beta cells (insulin): it triggers insulin release only when blood sugar is high — a "glucose-dependent" effect. This is why liraglutide rarely causes dangerous low blood sugar on its own, unlike insulin or sulfonylureas.
• Pancreatic alpha cells (glucagon): it suppresses glucagon, the hormone that tells your liver to dump sugar into the blood, lowering fasting glucose.
• Brain (appetite): it activates GLP-1 receptors in appetite-control centers of the hypothalamus and brainstem, reducing hunger and how much you eat — the main driver of weight loss.
• Stomach (fullness): it slows gastric emptying, so food stays in your stomach longer and you feel full sooner. This also smooths out post-meal blood-sugar spikes — and it is the direct cause of the nausea most people feel early on.
• Heart and blood vessels: beyond weight and glucose effects, the LEADER trial showed a direct cardiovascular benefit in high-risk diabetes patients (detailed below).^[2]

Natural GLP-1 has a half-life of only 1-2 minutes because the enzyme DPP-4 chews it up almost immediately. Liraglutide's albumin-binding fatty-acid chain is what defeats that enzyme and gives it a workable 13-hour half-life — but it still clears faster than semaglutide, which is the whole reason it needs daily rather than weekly dosing.^[6] Evidence level for mechanism: confirmed in humans, not extrapolated from animals.

How to read this section: for each benefit we give the plain-English claim, the mechanism, the population actually studied, the effect size, and the limitation. The good news with liraglutide is that these come from large human randomized controlled trials (RCTs), not rodent studies — so the evidence bar here is genuinely high.

Weight loss (in people without diabetes)

Claim: meaningful, sustained weight loss. Mechanism: reduced appetite (brain) plus slower gastric emptying (fullness). Population: SCALE Obesity and Prediabetes randomized 3,731 adults without type 2 diabetes for 56 weeks. Effect: liraglutide 3.0 mg produced mean weight loss of 8.4 kg versus 2.8 kg on placebo (about 5.6 kg, or roughly 5-6% of body weight, beyond placebo); 63.2% of patients lost at least 5% of body weight and 33.1% lost more than 10%, versus 27.1% and 10.6% on placebo.^[1] Limitation: results vary widely between individuals, and weight is regained after stopping (see below). This is the core evidence behind the weight-loss use case.

Weight loss (in people with type 2 diabetes)

Claim: weight loss plus better blood-sugar control. Mechanism: same appetite and satiety effects, plus glucose-dependent insulin and glucagon suppression. Population: SCALE Diabetes, adults with type 2 diabetes. Effect: liraglutide 3.0 mg produced about 6% mean weight loss alongside significant HbA1c (blood-sugar) reduction.^[3] Limitation: weight loss in diabetes is consistently somewhat lower than in people without diabetes — a pattern seen across the whole GLP-1 class.

Cardiovascular protection

Claim: fewer heart attacks, strokes, and cardiovascular deaths in high-risk patients. Mechanism: a mix of weight, blood-pressure, glucose, and likely direct vascular effects. Population: the LEADER trial enrolled 9,340 type 2 diabetes patients at high cardiovascular risk, followed a median of 3.8 years. Effect: liraglutide 1.8 mg cut the primary composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, with a hazard ratio of 0.87 (13% relative reduction; 95% CI 0.78-0.97; events 13.0% vs 14.9% on placebo).^[2] Limitation: this was demonstrated in high-risk diabetes patients — it should not be assumed to apply to a healthy person taking it purely for weight loss. Still, it made liraglutide the first GLP-1 agonist to prove a hard cardiovascular outcome benefit.

Blood-sugar control

Claim: lowers HbA1c with low hypoglycemia risk. Mechanism: glucose-dependent insulin release plus glucagon suppression and slowed gastric emptying. Population: type 2 diabetes patients across the SCALE and LEADER programs. Effect: clinically meaningful HbA1c reductions with little risk of low blood sugar when used alone, because insulin is only stimulated when glucose is elevated.^[3] Limitation: hypoglycemia risk rises sharply when combined with insulin or sulfonylureas.

Weight maintenance after dieting

Claim: helps hold onto (and add to) weight already lost. Mechanism: continued appetite suppression counteracting the body's tendency to regain. Population: SCALE Maintenance randomized adults who had first lost at least 5% of body weight through a low-calorie diet. Effect: the liraglutide 3.0 mg group maintained and added to their loss over 56 weeks, while the placebo group regained.^[4] Limitation: the benefit depends on staying on the drug.

Adolescent obesity

Claim: effective in teens, not just adults. Mechanism: identical to adults. Population: SCALE Teens randomized 251 adolescents aged 12 to under 18. Effect: liraglutide 3.0 mg significantly reduced BMI standard-deviation score versus placebo at week 56, which is the evidence that supported the 2020 adolescent Saxenda approval.^[5] Limitation: long-term pediatric data remain more limited than the adult dataset.

The honest bottom line on benefits

• The human evidence is strong — this is genuine RCT and cardiovascular-outcomes data, not animal extrapolation.
• But it is less powerful than newer drugs. Semaglutide 2.4 mg produced roughly 15% weight loss versus liraglutide's ~8%, and tirzepatide more still — so on weight loss alone liraglutide is now a second-tier choice.
• Weight regain is expected after stopping. The SCALE follow-up work showed patients regain much of the lost weight within a year of discontinuation. Liraglutide manages weight; it does not "reset" it.

Read this first: liraglutide is a prescription drug with FDA-defined dosing, so unlike the research peptides on this site there are validated human doses. It is the same molecule across brands — only the target dose differs by indication. All dosing is once-daily subcutaneous (under-the-skin) injection from a pre-filled pen; no reconstitution or mixing is required.

FDA-approved doses by brand and indication

Brand	Indication	Starting dose	Target dose	Population
Victoza	Type 2 diabetes	0.6 mg/day × 1 wk	1.2 mg → 1.8 mg/day	Adults & children ≥10 y
Saxenda	Chronic weight management	0.6 mg/day × 1 wk	3.0 mg/day	Adults (BMI ≥30, or ≥27 with comorbidities); adolescents 12-17 y

The 0.6 mg starting dose is deliberately below the effective range — it exists only to let your gut get used to GLP-1 activation and blunt nausea. Doses below 1.2 mg do not produce meaningful glucose or weight effects.^[8]

Saxenda weight-management escalation schedule

From the FDA Saxenda label.^[7] Each step lasts at least one week:

Week	Dose	Notes
Week 1	0.6 mg/day	Acclimation dose
Week 2	1.2 mg/day	—
Week 3	1.8 mg/day	—
Week 4	2.4 mg/day	—
Week 5+	3.0 mg/day (target)	Maintenance

This slow ramp is not optional — starting at the full 3.0 mg dose causes severe nausea and vomiting in most people, and GI intolerance is the number-one reason people quit. If you cannot tolerate a step, the label says hold at the current dose for an extra week before retrying. If 3.0 mg still cannot be tolerated after extended titration, the label recommends discontinuation, because there is no approved Saxenda maintenance dose below 3.0 mg. And if you have not lost at least 4% of body weight after 16 weeks at 3.0 mg, the label suggests reassessing — that is the checkpoint where non-responders are identified.

Victoza type 2 diabetes escalation schedule

From the FDA Victoza label.^[8] Unlike Saxenda, Victoza does not require titrating all the way to the maximum:

Week	Dose	Notes
Week 1	0.6 mg/day	Acclimation
Week 2+	1.2 mg/day	Effective glycemic dose for many patients
Week 3+ (if needed)	1.8 mg/day	Maximum, only if 1.2 mg is insufficient

Injection technique

• Pen format: liraglutide comes in pre-filled multi-dose pens — no reconstitution math and no separate bacteriostatic water, unlike lyophilized research peptides.
• Sites: abdomen (at least 5 cm from the navel), front of thigh, or back of the upper arm. Rotate sites daily to avoid lumpy tissue buildup (lipohypertrophy).
• Timing: any time of day, with or without meals. Pick a consistent time and stick to it.
• Needle: use a fresh pen needle each time; dispose in an FDA-cleared sharps container. Perform the flow check before first use of a new pen.

For a step-by-step walkthrough, see the injection technique guide.

Missed doses and restarting

• Within about 12 hours of your usual time: take it when you remember, then resume the normal schedule.
• More than 12 hours late: skip it and take the next scheduled dose — never double up.
• More than 3 consecutive days missed: your GI tolerance has likely reset. Restart at 0.6 mg and re-titrate; resuming at your old dose causes severe nausea.

Storage

• Unopened pens: refrigerate at 2-8°C (36-46°F). Do not freeze.
• In-use pens: keep at room temperature (up to 30°C / 86°F) or refrigerated for up to 30 days after first use, then discard.
• Visual check: the solution should be clear and colorless — discard if cloudy, discolored, or containing particles.

See the broader peptide storage guide for travel and handling tips.

Straight talk: liraglutide has the longest real-world safety record of any GLP-1 drug — FDA-approved since 2010, with the LEADER (9,340 patients, 3.8 years) and SCALE (3,731 patients, 56 weeks) trials plus over a decade of post-marketing use behind it.^[2][1] The side-effect profile is therefore very well characterized. The main day-to-day issue is gastrointestinal discomfort during dose titration; the headline warnings (thyroid, pancreatitis, gallbladder) are class-wide and mostly rare.

Side effects by frequency (SCALE trial, Saxenda 3.0 mg vs placebo)

Effect	Saxenda 3.0 mg	Placebo	Notes
Nausea	39.3%	13.8%	Most common; peaks during titration, then declines
Diarrhea	20.9%	9.9%	Usually mild to moderate
Constipation	19.4%	8.5%	From slowed gastric motility
Vomiting	15.7%	3.9%	Dose-related, worst during ramp-up
Headache	13.6%	12.6%	Often transient
Decreased appetite	10.0%	1.4%	A pharmacological effect, not really an "adverse" one
Cholelithiasis (gallstones)	2.5%	1.0%	Likely from rapid weight loss (~2.5× increase)
Hypoglycemia (non-diabetic, monotherapy)	1.6%	1.1%	Low alone; rises sharply with insulin/sulfonylureas
Acute pancreatitis (LEADER)	0.4%	0.5%	Not increased vs placebo, but a class warning
Discontinuation for adverse events	9.8%	4.3%	Mostly GI-driven

A small mean heart-rate rise of 2-3 bpm is also seen across trials.^[1] Most people who tolerate the first four weeks of titration can reach and stay on target dose; eating smaller, lower-fat meals and staying hydrated helps with the GI symptoms.

Boxed warning: thyroid C-cell tumors

Both the Saxenda and Victoza labels carry a boxed warning for thyroid C-cell tumors, based on rodent studies where long-term GLP-1 exposure produced dose-dependent C-cell hyperplasia and medullary thyroid carcinoma (MTC).^[7] Human relevance is uncertain: rodent thyroid C-cells carry far more GLP-1 receptors than human C-cells, and more than a decade of clinical use has not produced a confirmed human MTC signal. The warning stays because MTC is rare enough that even a small increase would take enormous datasets to detect, and the FDA cannot fully rule it out. Absolute contraindications: a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia type 2 (MEN 2). Important nuance: this applies only to MTC — not the far more common papillary or follicular thyroid cancers. If a family member had "thyroid cancer," find out which type before assuming you are contraindicated.

Pancreatitis and gallbladder events

Acute pancreatitis is a class warning across all GLP-1 drugs. In LEADER the rate was 0.4% on liraglutide vs 0.5% on placebo — not increased, but the label still warns to watch for it. Persistent severe abdominal pain, often radiating to the back with nausea, means stop the drug and get evaluated; if pancreatitis is confirmed, do not restart. A prior history of pancreatitis is a relative contraindication. Gallstones roughly doubled to 2.5% (from 1.0% on placebo), most likely a consequence of rapid weight loss itself rather than a direct drug effect — gallstones are a known risk of any fast weight-loss method. Right-upper-quadrant pain after fatty meals or jaundice warrants an ultrasound.

Contraindications and who should avoid it

• Personal/family history of MTC or MEN 2: absolute contraindication (boxed warning).
• Pregnancy: discontinue at least 2 months before planned conception; not used in pregnancy.
• Breastfeeding: not recommended.
• History of pancreatitis: relative contraindication.
• Type 1 diabetes: not approved for primary glucose management.
• Severe GI disease (gastroparesis, active IBD flare): avoid.
• Known hypersensitivity to liraglutide or its excipients.

Drug interactions

• Insulin / sulfonylureas: hypoglycemia risk — those drugs usually need dose reduction.
• Oral medications (oral contraceptives, levothyroxine, warfarin, narrow-therapeutic-index drugs): slowed gastric emptying can alter absorption, so monitor levels/INR and separate timing where advised.
• Other GLP-1 agonists (semaglutide, tirzepatide, dulaglutide, exenatide): do not combine — switch directly instead.

When to seek care: severe persistent abdominal pain (pancreatitis), right-upper-quadrant pain or jaundice (gallbladder), a neck mass, hoarseness or trouble swallowing (thyroid), or any allergic reaction. For general context, see Are Peptides Safe? and Peptide Side Effects.

Why this section is different for liraglutide: unlike the unapproved research peptides elsewhere on this site, liraglutide is a fully FDA-approved prescription drug. The gold-standard "source" is a pharmacy-dispensed, prescriber-supervised Victoza or Saxenda pen — a regulated product with a known identity, purity, and cold chain. That is the safest route by a wide margin.

Legal and regulatory status (2026)

• FDA-approved: Victoza (type 2 diabetes, 2010) and Saxenda (chronic weight management, 2014), same molecule, different dose targets.^[7][8]
• Prescription-only: it is a legally prescribed drug, not a "research chemical." It is not a DEA-controlled substance.
• Boxed warning for thyroid C-cell tumors, with MTC and MEN 2 as contraindications — a real regulatory constraint, not marketing boilerplate.
• Sports: not a standard banned substance the way many research peptides are, but competitive athletes should always verify current anti-doping rules for their sport.

Grey-market and compounded liraglutide — read the caution

Because brand-name pens are expensive and insurance coverage for obesity is patchy, some people encounter compounded or research-labeled liraglutide sold outside the normal pharmacy channel. Treat these with caution:

• Purity and identity vary. Product sold as a "research" peptide has no guarantee it is actually liraglutide at the stated concentration or purity. If you go this route despite the risks, insist on a batch-specific third-party Certificate of Analysis (COA) with HPLC purity (look for ≥98%) and mass-spectrometry identity confirmation.
• Endotoxin testing (LAL) matters for anything injected.
• Red flags: no COA (or a seller-issued one), pre-mixed "ready to use" liquid, prices far below market, or explicit human-dosing instructions from a non-pharmacy vendor.
• Cold chain: liraglutide must stay refrigerated before first use — mishandled shipping degrades it.

Bottom line: for a drug that already has an FDA-approved, insurance-billable form with a boxed warning, the sensible path is a prescription under medical supervision. The savings from a grey-market vial rarely justify the loss of guaranteed identity, purity, and clinical oversight. For the full legal picture, read Are Peptides Legal?

Both drugs come from Novo Nordisk and share the GLP-1 mechanism, but semaglutide is a meaningful pharmacokinetic upgrade. Here is how they compare:

Feature	Liraglutide (Saxenda)	Semaglutide (Wegovy)
Half-life	~13 hours	~7 days
Dosing	Daily injection	Weekly injection
Weight loss (mean, trial)	~8% (SCALE)	~15% (STEP 1)
Cardiovascular trial	LEADER (type 2 diabetes)	SELECT (obesity without diabetes)
Pediatric approval	Ages 12+	Ages 12+
Oral formulation	No	Yes (Rybelsus, for diabetes)
Real-world safety history	10+ years	~5 years

Semaglutide's roughly 15% mean weight loss is nearly double liraglutide's ~8%, and weekly dosing is simply more convenient, which is why semaglutide has largely displaced liraglutide in practice. Liraglutide's remaining edges are its longer safety track record and its daily schedule, which lets GI-sensitive patients fine-tune the dose. For the full breakdown, see our semaglutide vs liraglutide comparison.

Liraglutide pioneered GLP-1 therapy for obesity, but newer compounds now offer greater efficacy. For the full class overview, see the complete GLP-1 guide.

• Semaglutide (Ozempic/Wegovy): liraglutide's direct successor from Novo Nordisk — roughly 15% weight loss with weekly dosing, and now an oral option.
• Tirzepatide (Mounjaro/Zepbound): a dual GLP-1/GIP agonist with up to about 22.5% weight loss, the most effective FDA-approved option to date.
• Retatrutide: an investigational triple GLP-1/GIP/glucagon agonist showing up to ~24% weight loss in Phase 2 — the current frontier.
• Cagrilintide (CagriSema): an amylin analog paired with semaglutide for complementary appetite suppression.
• Survodutide and mazdutide: dual GLP-1/glucagon agonists with particular promise for liver-fat reduction and MASH.